Ionis Pharmaceuticals, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
IONS Nasdaq 2830 www.ionis.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals (IONS) Signs Recordati Deal For Zilganersen Outside The U.S. - Jun 28th, 2026 12:06 pm
Ionis Pharmaceuticals (IONS) Is Up 9.5% After FDA Expands Tryngolza Label For Severe Hypertriglyceridemia - Jun 27th, 2026 9:11 pm
IONS Out-Licenses ex-U.S. Rights for Rare Neurology Drug to Recordati - Jun 26th, 2026 8:43 am
Ionis grants Recordati rights to zilganersen for Alexander disease - Jun 26th, 2026 4:17 am
FDA Expands IONS' Tryngolza Label to Treat Severe Hypertriglyceridemia - Jun 25th, 2026 11:29 am
Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S. - Jun 25th, 2026 12:59 am
IONS Stock Jumps 4% After-Hours — Goldman Sachs Lifts Price Target On Tryngolza Approval - Jun 24th, 2026 5:54 pm
TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG) - Jun 24th, 2026 12:37 pm
Ionis, with new FDA nod, hits a ‘commercial inflection point’ - Jun 24th, 2026 10:50 am
How Kardigan spun deal leftovers into a $400M IPO - Jun 23rd, 2026 4:21 am
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now - Jun 19th, 2026 6:24 am
Is lonis Pharmaceuticals, Inc. (IONS) Among the Best Genomics Stocks to Buy According to Analysts? - Jun 16th, 2026 6:52 am
Intellia Surges; Can Its Gene-Editing Drug Solve The Chronic Treatment Problem? - Jun 15th, 2026 3:10 pm
Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors - Jun 8th, 2026 5:00 am
Assessing Ionis Pharmaceuticals (IONS) Valuation After New Olezarsen Data Plans And Bullish Pipeline Updates - Jun 6th, 2026 9:11 am
Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses - Jun 4th, 2026 5:00 am
This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter - May 31st, 2026 2:16 pm
Why Is Ionis Pharmaceuticals (IONS) Up 3.4% Since Last Earnings Report? - May 29th, 2026 9:30 am
GSK’s hepatitis B drug touts functional curative potential in double Phase III win - May 29th, 2026 4:16 am
Why The Story Around Ionis Pharmaceuticals (IONS) Is Shifting After Fresh Analyst Targets And Guidance - May 28th, 2026 7:03 pm